8-K: Seres Therapeutics Reports Positive SER-155 Data in irEC

Seres Therapeutics announced encouraging top-line results from an investigator-sponsored trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC).

Summary

• Seres Therapeutics announced top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in 15 patients with moderate-to-severe immune checkpoint inhibitor-related enterocolitis (irEC).
• The primary endpoint was met, with 80% (12 of 15) of participants achieving an immunosuppressive-free clinical response at Day 15, defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy.
• Notably, 33% (5 of 15) achieved complete clinical remission (Grade 0 diarrhea) without immunosuppressive therapy at Day 15.
• At Day 43, 13% (2 of 15) maintained immunosuppressive-free complete clinical remission, and 33% (5 of 15) maintained immunosuppressive-free clinical response.
• SER-155 was generally well tolerated through Day 43, with no serious adverse events assessed as related to the drug.
• Pharmacology data showed robust SER-155 bacterial strain engraftment and statistically significant reductions in biomarkers of gastrointestinal inflammation and mucosal epithelial barrier integrity by Day 43.
• These results support the continued development of SER-155 for irEC, a condition that affects approximately 25% of immune checkpoint inhibitor (ICI) therapy recipients and often requires halting cancer treatment.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the strong primary endpoint results and favorable safety profile, indicating potential for SER-155 in a significant unmet medical need, though further development and funding are required.

Positives

• 80% of participants achieved an immunosuppressive-free clinical response at Day 15, meeting the primary endpoint.
• 33% of participants achieved complete immunosuppressive-free clinical remission at Day 15.
• SER-155 was generally well tolerated with no serious adverse events assessed as related to the drug.
• Pharmacology data demonstrated robust bacterial strain engraftment and improvements in GI inflammation and barrier integrity biomarkers.
• The results support continued development of SER-155 for irEC, addressing a significant unmet need.
• SER-155 has the potential to allow patients to continue life-saving ICI cancer treatment without disruption.

Negatives

• Only 13% of participants maintained complete immunosuppressive-free clinical remission at Day 43.
• 7 out of 12 responders at Day 15 required non-systemically acting, gastrointestinal-targeted immunosuppressives after Day 15.
• The company has incurred significant losses and is not currently profitable, with ongoing need for additional funding.

Risks

• Need for additional funding.
• Ability to continue as a going concern.
• Incurrence of significant losses and potential for never becoming profitable.
• Cost reduction actions may not achieve intended benefits or extend cash runway.
• Limited operating history.
• Potential inability to realize anticipated benefits from the VOWST sale and facing new challenges as a smaller company.
• Risk of receiving notice of failure to satisfy Nasdaq listing rules.
• Novel approach to therapeutic intervention carries inherent risks.
• Reliance on third parties for clinical trials and manufacturing.
• Ability to achieve market acceptance for commercial success.
• Competition faced by the company.
• Ability to protect intellectual property.
• Impact of recent management transitions and appointments and ability to retain key personnel.
• Disruptions at the FDA or other government agencies.

Future Outlook

The company is engaging with potential partners and financing sources to advance the development of SER-155 in irEC and for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT). The company projects its cash runway well into Q1 2027. Further development in other inflammatory and immune diseases is also being considered.

Management Comments

• "We are extremely pleased with the study data from our long-time collaborator, MSK, which highlight SER-155s potential as a non-immunosuppressive treatment for irEC, which could enable patients to continue their ICI cancer treatment."
• "We are engaging with potential partners, including companies with ICI franchises, as we evaluate next steps for the development of SER-155 in irEC."
• "We also continue to engage with potential collaborators and financing partners as we seek funding to advance the Phase 2 study of SER-155 in allo-HCT, and development in our broader pipeline."
• "These clinical and pharmacological results underscore the potential of SER-155 to address mucosal epithelial barrier dysfunction and gastrointestinal inflammation through disease pathways not targeted by existing therapies."
• "Beyond irEC, we believe these encouraging data support continued development of Seres live biotherapeutic platform to target microbe-specific functions linked to multiple inflammatory and immune diseases in addition to irEC, such as ulcerative colitis and Crohns disease."
• "These results suggest SER-155 may offer a promising, novel approach to managing irEC, with the potential to reduce reliance on systemic immunosuppressive therapies, while also helping patients continue ICI treatment."
• "We look forward to continued development to further understand the role microbiome therapeutics could play in this setting and the broader opportunity to support the growing number of patients receiving checkpoint inhibitors across multiple cancer types."

Industry Context

StockSavvy.ai notes that the results for SER-155 in irEC align with the growing interest in microbiome-based therapeutics for inflammatory and immune-related conditions, particularly those that can mitigate side effects of other treatments like immune checkpoint inhibitors. The potential to allow patients to continue life-saving cancer therapies is a significant value proposition in the competitive oncology landscape.

Comparison to Industry Standards

• The primary endpoint of 80% immunosuppressive-free clinical response at Day 15 in irEC patients is a strong outcome, especially considering the limitations of current standard of care which involves systemic immunosuppressives and often halts cancer treatment.
• The 33% complete remission rate at Day 15 is also a notable achievement, though maintenance of this remission at Day 43 (13%) indicates a need for further optimization or longer treatment durations.
• The safety profile, with no drug-related serious adverse events, is highly favorable and aligns with the general expectation for live biotherapeutics to have a better safety profile than traditional small molecules or biologics, particularly in vulnerable patient populations.
• The observed engraftment and biomarker changes in SER-155 are consistent with the known mechanisms of action for Seres' live biotherapeutics platform, supporting the scientific rationale for its use in inflammatory conditions.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial results may lead to increased investor confidence, but the need for further funding and the company's profitability status remain key considerations.
• Patients: Potential for a new, non-immunosuppressive treatment option for irEC that could allow them to continue life-saving cancer therapy.
• Healthcare Providers: Offers a novel therapeutic approach to manage a challenging side effect of ICI therapy, potentially improving patient outcomes and quality of life.
• Potential Partners: The positive data may attract strategic partnerships for further development and commercialization of SER-155.

Next Steps

• Continued development of SER-155 to treat irEC.
• Engagement with potential partners for SER-155 development.
• Seeking funding to advance the Phase 2 study of SER-155 in allo-HCT.
• Continued engagement with potential collaborators and financing partners.
• Presentation of IST results at a future medical conference.
• Advancing IND-enabling studies for SER-603 for inflammatory bowel disease.

Key Dates

Recommendation

The positive clinical data for SER-155 in irEC is encouraging and addresses a significant unmet need. However, the company's ongoing need for funding, history of losses, and the early stage of development for SER-155 warrant a cautious 'hold' recommendation. Further clinical validation and successful financing will be critical for future upside.

Keywords

Seres Therapeutics, SER-155, irEC, Immune Checkpoint Inhibitor-Related Enterocolitis, Live Biotherapeutics, Microbiome, Gastrointestinal Inflammation, Clinical Trial, Oncology, Biotechnology